Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Trial of Brexpiprazole Once-weekly in Schizophrenia
NCT05326347Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- May 2022
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of brexpiprazole orally disintegrating tablet in schizophrenia, sponsored by Otsuka Pharmaceutical Co., Ltd.. Started May 2022; status: completed.
02
Drugs
brexpiprazole orally disintegrating tablet
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05326347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05326347.